Activist Yakira Demands Strategic Review at Atrium, Says Stock Trades Below Net Cash
RNA is trading near its 52-week low of $7.49 (3.1% above the low).
Summary
Yakira Capital publicly pressed Atrium's board to launch a strategic review, cut spending, and justify the $50M PIPE priced October 8 at $7.93 a share. Yakira says it raised concerns privately in mid-September and sent a detailed letter October 9 that the board never answered. Its core argument: Atrium held roughly $254M in net cash (~$14.85 a share) before the raise, so at under $8 the stock trades below net cash, assigning negative value to the BMS collaboration (up to $1.35B R&D plus $825M commercial milestones and low-double-digit royalties) and the ATR 1072/1086 pipeline. The stock is near its 52-week low of $7.49 and down about 44% from ~$14 pre-HARBOR. This is a small-cap (~$170M) with a credible activist pushing for a sale or partnership, which can force board action or draw other bidders. Watch for any board response or formation of a special committee; proof-of-concept data isn't expected until the second half of 2027.
At the time of this announcement, RNA was trading at $7.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.5M. The 52-week trading range was $7.49 to $16.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.